Merck makes big antiviral move with $9B Cidara deal

Merck's Cidara Therapeutics acquisition brings a lead program with potential to become a first-in-class drug for preventing influenza infection. A Phase 3 study is already underway, timed to coincide with the start of the flu season in the Northern Hemisphere.

Editor's Pick

Top Story Merck Makes Big Antiviral Move With $9B Deal to Land Cidara's Late-Stage Drug for Flu Prevention Merck's Cidara Therapeutics acquisition brings a lead program with potential to become a first-in-class drug for preventing influenza infection. A Phase 3 study is already underway, timed to coincide with the start of the flu season in the Northern Hemisphere. Sponsored How AI is Reshaping Care Navigation and Patient Outcomes Presented by Quantum Health In this episode, Quantum Health's Chief AI Officer, Shannon Skaggs joins the podcast.  We'll cover the importance of completeness and quality of data and how AI can be used for a patient's personal health journey. Listen now!

Featured News

AI Companies That Invest in Better Data Pipelines are Winning Faster Regulatory Approvals — Here's Why Medical AI developers who prioritize data early will be the ones crossing the regulatory finish line faster and more reliably. What Excites Zimmer Biomet's CIO About MedTech Right Now? Shaun Braun, Zimmer Biomet's chief information and technology officer, said today's biggest medtech innovation is the field's focus on connection and interoperability. By integrating data, AI and robotics into a single ecosystem, the company is seeking to deliver more personalized care and improve surgical outcomes.

Video   Video: Looking for smarter health guidance? Carolyn Jasik from Verily talks about their telemedicine app linking users to licensed doctors and Violet, an AI that answers your health questions using your own medical records. Watch the interview to see how Verily is changing health access.

Resources

MedCity FemFwd: Inside Wellcome Leap and Pivotal's $100M Commitment To Women's Health In this episode, we're joined by Dr. Renee Wittemyer, vice president of program strategy at Pivotal Ventures, and Dr. Regina Dugan, CEO of Wellcome Leap. They discuss the organizations' recent $100 million commitment to accelerate women's health research. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe